Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia

Outcomes after late bone marrow and very early central nervous system relapse of childhood B-Acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433

(2020) Glen Lew et al.   HAEMATOLOGICA

Children’s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

(2020) Kimberly P. Dunsmore et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial

(2019) Catriona Parker et al.   Lancet Haematology

Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics

(2019) Cornelia Eckert et al.   JOURNAL OF CLINICAL ONCOLOGY

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

(2018) Nicola Gökbuget et al.   BLOOD

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia

(2017) Trausti Oskarsson et al.   PEDIATRIC BLOOD & CANCER

A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy

(2016) Sindhu Cherian et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group Study AALL0232

(2016) Eric C. Larsen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

(2016) Arend von Stackelberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients

(2015) M. A. Pulsipher et al.   BLOOD

Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2

(2015) Elizabeth A. Raetz et al.   PEDIATRIC BLOOD & CANCER

How I treat relapsed childhood acute lymphoblastic leukemia

(2012) F. Locatelli et al.   BLOOD

Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90

(2010) Gesche Tallen et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial

(2010) Catriona Parker et al.   LANCET

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

(2008) M. J. Borowitz et al.   BLOOD

Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study

(2008) K Nguyen et al.   LEUKEMIA